An early-stage CRISPR-based therapy dramatically reduced LDL cholesterol and triglycerides in a small cohort of patients with heart disease, investigators reported at the American Heart Association meeting and in the New England Journal of Medicine. The first-in-human data, led by CRISPR Therapeutics among others, demonstrate potent, durable lipid lowering after a single administration. Researchers cautioned about potential liver toxicities and ethical considerations around permanent editing for common conditions; the study remains small and exploratory.